Glucagon like Peptide 1 News and Research

RSS

Consistent meal logging drives major weight loss in app users

The people who log their meals most days of the week lose the most weight. This is the central finding of a peer-reviewed study of 5132 MyNetDiary users, published on August 13, 2026, in the Journal of Medical Internet Research.

25 Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

24 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

What happens to body fat when people follow the Eatwell Guide?

Higher adherence to the UK Eatwell Guide was associated with lower BMI, waist circumference, total body fat, and trunk fat in more than 156,000 UK Biobank participants. The associations persisted prospectively across demographic, physical activity, and genetic-risk groups, supporting the role of diet quality in weight management.

16 Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

10 Aug 2026

Mouse study shows how liraglutide briefly rewires gut bacterial communities

Researchers treated male high-fat-fed mice with liraglutide for 14 days, then tracked fecal bacterial communities after a 7-day washout using 16S rRNA sequencing. Liraglutide shifted the microbiome toward Lactobacillus- and Leptogranulimonas-related taxa while reducing several fermentative taxa, but most changes moved back toward baseline after treatment stopped.

4 Aug 2026

$GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes$

GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes

New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes.

4 Aug 2026

Food may taste different on GLP-1 drugs, but taste may not be the reason

The review suggests that patient-reported “taste changes” during GLP-1RA treatment may reflect reduced food enjoyment and motivation rather than consistent impairment of basic taste. The authors propose a sensory-liking-wanting framework while emphasizing that current human evidence remains heterogeneous and largely indirect.

4 Aug 2026

Ten-million-person study links semaglutide to lower COVID-19 mortality

Researchers analyzing claims from more than 10.1 million commercial insurance and Medicare Advantage enrollees found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-related death. The observational findings corroborate earlier SELECT trial results but do not establish causation, making further prospective research essential.

30 Jul 2026

Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits

Newer GLP-1 receptor agonists, including semaglutide and tirzepatide, were associated with fewer alcohol-related ED visits or hospitalizations among adults with alcohol use disorder and type 2 diabetes or obesity.

24 Jul 2026

GLP-1 receptor agonists may increase hair loss risk

Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ today.

22 Jul 2026

Generic semaglutide could improve diabetes treatment affordability in Canada

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.

22 Jul 2026

Semaglutide vs. liraglutide: Head-to-head study reveals a diabetes risk difference

Researchers compared semaglutide with liraglutide in 57,456 insured adults without recorded diabetes or cardiovascular disease who initiated formulations indicated for chronic weight management. Semaglutide users had a lower risk of incident diabetes, particularly beyond six months of follow-up, but limited cardiovascular events prevented a precise comparison of cardiovascular risk.

20 Jul 2026

Semaglutide fuels rapid growth in US GLP-1RA use as payments rise

Nationally representative US data show GLP-1RA use rose 230% among adults with diabetes and 643% among those without reported diabetes between 2017 and 2022, largely driven by semaglutide. Mean annual out-of-pocket payments decreased, but mean total annual payments per user increased, raising concerns about long-term affordability.

20 Jul 2026

GLP-1 weight-loss drugs may also reduce binge eating

Research indicates GLP-1RAs may effectively reduce binge eating severity, offering a complementary approach to existing psychological therapies for obesity.

20 Jul 2026

Popular diabetes drugs do not alter the risk of developing a blinding eye condition

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of medication that mimics the GLP-1 hormone - to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

17 Jul 2026

Weight loss drugs may reduce binge eating disorder symptoms

Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder, in a new review of evidence led by University College London (UCL) researchers.

15 Jul 2026

GLP-1 receptor activation linked to lower depression and bipolar disorder odds

Genetic analyses linked BMI-related GLP-1 receptor activation to better mental well-being and lower odds of major depressive disorder and bipolar disorder. The findings do not prove that GLP-1 receptor agonist drugs treat psychiatric conditions, and randomized clinical trials are still needed.

15 Jul 2026

Semaglutide dose may matter more than weight loss for heart health

The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions.

14 Jul 2026

GLP-1 weight loss may reduce first-impression penalties in relationships and hiring

An NBER working paper found that GLP-1 initiation and associated weight loss were followed by higher partnership formation among initially single women and greater employment entry among women who were not employed. The findings suggest that part of the female obesity penalty may arise when prospective partners and employers form first impressions, although the observational analysis did not directly prove discrimination

13 Jul 2026